Novartis and Amgen axe BACE drug for Alzheimer's

Another Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end two pivotal studies involving a medicine targeting BACE.

Under threat from Novartis, Biogen hails new data from SMA d...

Under threat from a gene therapy from Novartis, Biogen is making the case for its drug Spinraza for the muscle wasting disease spinal muscular atrophy, with new data that it hopes persuades

Novartis secures initial block on Gilenya generics in US

Conatus axes staff after latest failure of Novartis-partnere...

Novartis closing in on deal with US government over bribery ...

Novartis is close to an agreement with the US government over allegations it bribed doctors to market its drugs, according to a press report.

Sanofi appoints former Novartis exec Hudson as CEO

Sanofi has appointed Novartis’ pharma chief Paul Hudson as chief executive to replace the retiring Olivier Brandicourt, prompting a reshuffle for its Swiss rival.